查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1591904

韩特氏症治疗市场：按治疗方法、最终用户划分 - 全球预测 2025-2030

Hunter Syndrome Treatment Market by Treatment (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), End User (Clinics, Home Healthcare, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

韩特氏症治疗市场2023年估值为10.9亿美元，预计2024年将达到11.7亿美元，复合年增长率为8.06%，到2030年将达到18.7亿美元。

韩特氏症，也称为黏多醣症II，是一种罕见的遗传性疾病，会影响Glico的酵素分解。治疗范围广泛，包括酵素替代疗法、造血干细胞移植以及旨在控制症状和改善患者生活品质的新基因疗法。这种治疗的需求源于疾病的进行性及其对身体肌肉骨骼、心血管和神经系统的重大影响。主要应用是药物的进步，特别是开发针对酵素缺乏的客製化治疗方法。最终用途主要是医院、专科诊所和研究机构。根据市场洞察，关键的成长要素包括对罕见疾病的认识不断提高、基因治疗的进步以及政府的支持措施。特别是，创新基因治疗平台的出现正在释放个人化医疗的潜在机会，并吸引渴望解决未满足的医疗需求的相关人员和投资者。然而，高昂的治疗成本、有限的患者群体和严格的监管途径等挑战可能会阻碍市场成长。此外，各地区获得医疗保健的机会不平等也是一个主要障碍。创新成熟的领域包括 CRISPR 等基因编辑技术、寻找用于早期诊断的生物标记以及开发新型递送系统以提高酵素替代疗法的有效性。探索整合人工智慧以加速药物开发进程的研究也很有前景。市场的性质是动态的和高度研究集中的，其特点是透过生物技术公司之间的策略联盟和研究合作来汇集专业知识。为了利用新的商机，产业相关人员将投资于合作研究和开发，优先考虑以患者为中心的策略，并倡导促进更快核准和更广泛地获得突破性治疗的政策框架。与患者倡导团体的合作还可以加速护理和治疗方法标准的发展。

主要市场统计
基准年[2023] 10.9亿美元
预测年份 [2024] 11.7亿美元
预测年份 [2030] 18.7亿美元
复合年增长率（%） 8.06%

市场动态：针对快速发展的韩特氏症治疗市场揭示的关键市场见解

韩特氏症治疗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 与韩特氏症相关的政府措施和提高意识
    • 新型疗法的可用性和推出以及强大的管道
    • 国家医疗保健支出增加
  • 市场限制因素
    • 治疗费用相对昂贵
  • 市场机会
    • 干细胞疗法等治疗方法的技术进步
    • 具有竞争性药物的强大药物开发
  • 市场挑战
    • 该领域缺乏熟练的专业人员

波特的五力：驾驭韩特氏症治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解韩特氏症治疗市场的外在影响

外部宏观环境因素在塑造韩特氏症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解韩特氏症治疗市场的竞争格局

对韩特氏症治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵韩特氏症治疗市场供应商的绩效评估

FPNV 定位矩阵是评估韩特氏症治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘韩特氏症治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对韩特氏症治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 政府措施和提高对韩特氏症的认识
      • 新治疗方法的可用性和推出以及强大的管道
      • 国家医疗保健支出增加
    • 抑制因素
      • 治疗费用相对较高
    • 机会
      • 干细胞疗法等治疗方法的技术进步
      • 优势药品强势发展
    • 任务
      • 缺乏该领域熟练的专业人员
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章韩特氏症治疗市场（依治疗）

  • 酵素替代疗法
  • 造血干细胞移植

第七章韩特氏症治疗市场：按最终用户

  • 诊所
  • 家庭保健
  • 医院

第八章美洲韩特氏症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区韩特氏症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲韩特氏症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • ARMAGEN, INC.
  • AVROBIO, Inc.
  • Bioasis Technologies, Inc.
  • CANbridge Life Sciences Ltd.
  • Clinigen Limited
  • Denali Therapeutics Inc.
  • GC Biopharma corp.
  • JCR Pharmaceuticals Co., Ltd.
  • RegenxBio Inc.
  • Sangamo Therapeutics, Inc.
Product Code: MRR-B9334AD6C5BB

The Hunter Syndrome Treatment Market was valued at USD 1.09 billion in 2023, expected to reach USD 1.17 billion in 2024, and is projected to grow at a CAGR of 8.06%, to USD 1.87 billion by 2030.

Hunter Syndrome, also known as Mucopolysaccharidosis II, is a rare genetic disorder affecting enzyme breakdown of glycosaminoglycans. The treatment scope encompasses enzyme replacement therapy, hematopoietic stem cell transplantation, and emerging gene therapies aimed at symptom management and improving patients' quality of life. The necessity of such treatments arises from the progressive nature of the disease and its significant impact on the body's musculoskeletal, cardiovascular, and nervous systems. The primary application lies in pharmaceutical advancements, specifically in developing tailored therapies to counteract enzyme deficiencies. End-use extends primarily across hospitals, specialized clinics, and research institutes. Market insights reveal that key growth factors include increased awareness of rare diseases, advancements in genetic therapies, and supportive government initiatives. Specifically, the advent of innovative gene therapy platforms has unlocked potential opportunities in personalized medicine, engaging stakeholders and investors keen on addressing unmet medical needs. However, challenges such as high treatment costs, limited patient populations, and stringent regulatory pathways can hamper market growth. Additionally, inequalities in healthcare access across regions present significant barriers. Areas ripe for innovation include gene-editing technologies like CRISPR, exploring biomarkers for early diagnosis, and developing novel delivery systems to improve the efficacy of enzyme replacement therapies. Research exploring the integration of artificial intelligence to expedite drug development processes also holds promise. The nature of the market is dynamic and highly research-intensive, characterized by strategic partnerships and collaborations among biotech firms to leverage collective expertise. To capitalize on emerging opportunities, industry players should invest in collaborative R&D, prioritize patient-centric strategies, and advocate for policy frameworks that facilitate faster approvals and wider access to breakthrough therapies. Engaging with patient advocacy groups can also enhance the development of care standards and therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 1.09 billion
Estimated Year [2024] USD 1.17 billion
Forecast Year [2030] USD 1.87 billion
CAGR (%) 8.06%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hunter Syndrome Treatment Market

The Hunter Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing government initiatives and awareness pertinent to Hunter syndrome
    • Availability and launch of novel therapies coupled with robust pipelines
    • Growing healthcare expenditure among the population
  • Market Restraints
    • Relatively high cost of the treatment
  • Market Opportunities
    • Technological advancement in the introduction of treatments such as stem cell therapy
    • Robust pharmaceutical development in competitive drugs
  • Market Challenges
    • Lack of skilled professionals in the field

Porter's Five Forces: A Strategic Tool for Navigating the Hunter Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hunter Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hunter Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hunter Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hunter Syndrome Treatment Market

A detailed market share analysis in the Hunter Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hunter Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hunter Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hunter Syndrome Treatment Market

A strategic analysis of the Hunter Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hunter Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include ARMAGEN, INC., AVROBIO, Inc., Bioasis Technologies, Inc., CANbridge Life Sciences Ltd., Clinigen Limited, Denali Therapeutics Inc., GC Biopharma corp., JCR Pharmaceuticals Co., Ltd., RegenxBio Inc., and Sangamo Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Hunter Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplant.
  • Based on End User, market is studied across Clinics, Home Healthcare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing government initiatives and awareness pertinent to Hunter syndrome
      • 5.1.1.2. Availability and launch of novel therapies coupled with robust pipelines
      • 5.1.1.3. Growing healthcare expenditure among the population
    • 5.1.2. Restraints
      • 5.1.2.1. Relatively high cost of the treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancement in the introduction of treatments such as stem cell therapy
      • 5.1.3.2. Robust pharmaceutical development in competitive drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled professionals in the field
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hunter Syndrome Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Enzyme Replacement Therapy
  • 6.3. Hematopoietic Stem Cell Transplant

7. Hunter Syndrome Treatment Market, by End User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Home Healthcare
  • 7.4. Hospitals

8. Americas Hunter Syndrome Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Hunter Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Hunter Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ARMAGEN, INC.
  • 2. AVROBIO, Inc.
  • 3. Bioasis Technologies, Inc.
  • 4. CANbridge Life Sciences Ltd.
  • 5. Clinigen Limited
  • 6. Denali Therapeutics Inc.
  • 7. GC Biopharma corp.
  • 8. JCR Pharmaceuticals Co., Ltd.
  • 9. RegenxBio Inc.
  • 10. Sangamo Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. HUNTER SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. HUNTER SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HUNTER SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HUNTER SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUNTER SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUNTER SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. HUNTER SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. HUNTER SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023